ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) faces a challenge from Lupin Inc. as they seek FDA approval for a generic version of neffy© nasal spray. SPRY is responding with a patent infringement lawsuit that could delay Lupin’s product launch by 30 months. The outcome could significantly impact SPRY’s market position and intellectual property rights.

Neffy is a key product for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) in treating severe allergic reactions. The company’s future success hinges on Neffy’s market demand and SPRY’s market position, which looks promising.

Headquartered in San Diego, California, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a biopharmaceutical company specializing in treatments for severe allergic reactions. Founded in 2015, the company aims to provide patient-friendly solutions.

While SPRY shows promise as an investment, other AI stocks may offer greater potential. Investors seeking undervalued AI stocks with growth opportunities should explore alternatives. For insights on a potentially lucrative AI stock in the current market landscape, check out our free report.

Read more at Yahoo Finance: ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA